Padlock Therapeutics was acquired by Bristol Myers Squibb for up to $600M

Padlock Therapeutics, a biotechnology company founded by Biochemistry and Molecular Pharmacology professor Paul Thompson, was recently acquired by Bristol Myers Squibb for up to $600M if certain milestones are met.  Padlock Therapeutics, which was founded based on research from the Thompson lab, is focused on developing inhibitors targeting the Protein Arginine Deiminases, a family of enzymes whose activity is dysregulated in a variety of autoimmune disorders and cancers.

About Thompson Lab: http://www.umassmed.edu/thompson

More about this news:
http://www.genengnews.com/gen-news-highlights/bms-to-acquire-padlock-therapeutics-for-up-to-600m/81252509/

▴ Back To Top
Section Menu To Top